Dazolicine is an anti-arrhythmic compound, developed by the German company Roechlingsche Eisen & Stahl. In patients with various types of arrhythmia, after i.v. injection the drug proved to have very strong antiarrhythmic potency and rather a low incidence of side effects. After oral treatment, ectopic beats were eliminated in only 4 of 10 patients.

Deanol is a chemical compound that is involved in the biosynthesis of the neurotransmitter acetylcholine. Deanol aceglumate is marketed in Russia as a hepatoprotector and neurometabolic stimulator for the treatment of asthenic and astheno-depressive disorders, neuroleptic syndrome, alcohol withdrawal syndrome, neurotic and neurosis-like disorders, acute and chronic hepatitis, cirrhosis of the liver, cholestasis, fatty liver dystrophy of various genesis.

Motrazepam (Ro06-9098) is a benzodiazepine derivative patented by a Swiss multinational healthcare company Hoffmann-La Roche as anticonvulsants, muscle relaxants, and sedative agent.

Moxicoumone is orally available coumarin derivative patented by Francesco, Vismara, Societa per Azioni for capillary fragility treatment

Murocainide is aminoalkoxybenzofuran derivative patented by pharmaceutical company Delalande S. A. for ventricular tachycardia treatment. At 5 mg/kg i.v. in dogs Murocainide reversed ouabain-induced ventricular tachycardia.

Pimelautide is the immunomodulating lipopeptides lauroyl-L-Ala-gamma-D-Glu-LL-A2pmNH2-Gly. Pimelautide is an immunostimulant active on macrophages, polymorphonuclear leukocytes, T-lymphocytes, and NK cells, which in mice enhances delayed type hypersensitivity reactions, antibody production and resistance to bacterial infections. It was found to protect mice against the hepatotoxicity of paracetamol, which is due to cytochrome P-450 dependent formation of toxic metabolites and radicals. It decreased the amount of hepatic microsomal cytochrome P-450, and the level of CCl4-induced lipid peroxidation.

Nitroxinil is an anthelmintic drug mainly used for the control of liver fluke in sheep and cattle. Nitroxinil is active against the liver fluke the Fasciola hepatica and to a lesser extent against thread worms in the gastrointestinal tract. The efficacy of nitroxinil administered once by subcutaneous injection at a dosage regimen of 20 mg/kg live mass was evaluated against natural infestations of parafilaria bovicola in cattle. Trial animals were slaughtered 14 weeks after treatment. Treatment reduced the number of bleeding points by 97,8%, eosinophil-positive carcass lesions by 85,7% and eosinophil-positive lesion area by 92,8%, compared with controls.

ROTAMICILLIN was developed as an antibiotic that has never been marketed.

Bardoxolone methyl, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me or RTA 402, is one of the derivatives of synthetic triterpenoids. Bardoxolone methyl directly blocks IKKbeta activity and thereby the NF-kappaB pathway by interacting with Cys-179 in the IKKbeta activation loop. Binding of bardoxolone methyl to Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1) disrupts its critical cysteine residues, leading to the release of the nuclear factor erythroid 2-related factor 2 (Nrf2), which hinders its ubiquitination and finally leads to its stabilization and nuclear translocation. In the nucleus, Nrf2 activates the transcription of phase 2 response genes, leading to a coordinated antioxidant and anti-inflammatory response. In addition, it acts as an antagonist of the peroxisome proliferator-activated receptor gamma. Through Keap1/Nrf2 and nuclear factor-κB pathways, this agent can modulate the activities of a number of important proteins that regulate inflammation, redox balance, cell proliferation and programmed cell death. This agent is generally well tolerated, but it may increase adverse cardiovascular events. Presently, it is being further tested for the treatment of patients with chronic kidney disease, cancer, and pulmonary arterial hypertension.

Boehringer Ingelheim developed samixogrel as thromboxane A2 receptor antagonists. This drug participated in clinical trials for the treatment patients with diabetic complications, thrombosis, and unstable angina pectoris. However, all these studies were discontinued.